Catalent Applied Drug Delivery Institute To Collaborate With Lung Cancer Alliance To Conduct Patient Research

Somerset, N.J. — The Catalent Applied Drug Delivery Institute today announced that it is to collaborate with the Lung Cancer Alliance on patient research in early October. The collaboration will focus on patient and caregiver insights, in order to better understand the unmet needs of patients when managing lung cancer, also the impact that treatment has on the patient overall, managing other disease states, and daily living.

"The Institute's mission is dedicated to improving the patient experience through optimized drug delivery. This research is an important first step in developing meaningful patient insights regarding common barriers to adherence and other impacts," commented Terry Robinson, Executive Director, Catalent Institute."Our joint goal is to help create better patient outcomes."

"As the leading non-profit organization providing support for those touched by lung cancer, we are always looking for innovative ways to make patients' lives easier,"said Maureen Rigney, LICSW, Director of Community and Support Services for Lung Cancer Alliance. "This partnership with the Catalent Institute aims to do just that. We encourage our community to take part in this survey with the ultimate goal of improving their lives."

Established in 2012, the Catalent Applied Drug Delivery Institute employs a multi-tiered approach to accelerate the adoption of advanced drug delivery technologies through industry and academic collaboration, research, education, and the sharing of information. In June 2014, the Institute created the Non-Invasive Macromolecule Delivery Consortium (NMDC) as a number of working groups looking at alternative delivery routes to injection for biologics and other large molecule therapeutics.

For more details on the Catalent Institute, and follow the Catalent Institute on Twitter:@DrugDeliveryIns

Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]

Richard Kerns
+44 (0) 161 728 5880
[email protected]  


Catalent's Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments and foster industry collaboration on major issues pertaining to drug development, formulation and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.


Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J.  For more information visit

More products. Better treatments. Reliably supplied.™

Lung Cancer Alliance,, is the leading non-profit organization dedicated to saving lives and advancing research by empowering those living with and at risk for lung cancer. We offer personalized support, information and referral services at no cost through a team of trained, dedicated staff members to help patients, their loved ones and those at risk; Advocate for increased lung cancer research funding and equitable access, coverage and reimbursement for screening, treatment, diagnostics, and testing; conduct nationwide education campaigns about the disease, risk and early detection.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.